This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Daiichi Sankyo Company, Limited. Active years: 2015-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015-2017
Title: Takahide Aburatani: Innovator in Lipocalin Research
Introduction
Takahide Aburatani is a notable inventor based in Kashiwa, Japan. He has made significant contributions to the field of biochemistry, particularly in the development of novel lipocalin muteins. With a total of two patents to his name, his work focuses on innovative solutions in medical science.
Latest Patents
Aburatani's latest patents include "Nucleic acid molecules encoding muteins of human tear lipocalin which bind PCSK9." This patent relates to novel lipocalin muteins that bind to PCSK9, providing corresponding nucleic acid molecules and methods for their production. Another significant patent is "Human tear lipocalins which bind PCSK9 and methods of use thereof," which also focuses on lipocalin muteins and their applications in medical research.
Career Highlights
Takahide Aburatani is currently associated with Daiichi Sankyo Company, Limited, where he continues to advance his research in lipocalin technology. His work has implications for therapeutic developments in managing cholesterol levels and cardiovascular health.
Collaborations
Aburatani has collaborated with esteemed colleagues such as Gabriele Matschiner and Christine Rothe, contributing to a dynamic research environment that fosters innovation.
Conclusion
Takahide Aburatani's contributions to the field of lipocalin research exemplify the impact of innovative thinking in biochemistry. His patents reflect a commitment to advancing medical science and improving health outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile